Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: A multicenter retrospective series

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 916-924

  Rodrigues, M J ^a,b   Peron, J ^c,d   Frenel J S ^e   Vano, Y A ^f   Wassermann, J ^a,g   Debled, M ^h   Picaud, F ⁱ   Albiges, L ^j   Vincent Salomon, A ^k,l   Cottu, P H ^a  

^a INSTITUT CURIE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE LÉON BÉRARD   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e UMR INSERM U892 CNRS 6299   (France)

^f CENTRE ANTOINE LACASSAGNE   (France)

^g CENTRE RENÉ HUGUENIN   (France)

^h INSTITUT BERGONIÉ   (France)

ⁱ INSTITUT CLAUDIUS REGAUD   (France)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k Department of Tumor Biology and Pathology ^*  (France)

^l INSTITUT CURIE   (France)

more..

Author keywords

HER2 positive; Hormone receptors; T1abn0; Trastuzumab; Vascular emboli

Indexed keywords

HORMONE RECEPTOR; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CENTER; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ONCOGENE NEU; PARTIAL MASTECTOMY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK REDUCTION; TUMOR VOLUME;

EID: 84874657287     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds536     Document Type: Article

References (36)

1. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
2. Gianni L, Dafni U, Gelber RD et al.. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12: 236-244.
3. Joensuu H, Bono P, Kataja V et al.. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 2009; 27: 5685-5692.
4. Perez EA, Romond EH, Suman VJ et al.. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-3373.
5. Slamon D, Eiermann W, Robert N et al.. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-1283.
6. Spielmann M, Roche H, Delozier T et al.. Trastuzumab for patients with axillarynode-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 2009; 27: 6129-6134.
7. Schmidt F, Hartwagner KA, Spork EB et al. Medical audit after 26 711 breast imaging studies: improved rate of detection of small breast carcinomas (classified as Tis or T1a,b). Cancer 1998; 83: 2516-2520.
8. Fisher B, Dignam J, Tan-Chiu E et al.. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 2001; 93: 112-120.
9. Jubelirer SJ, Sutton J. Survival in patients with invasive breast cancers less than one centimeter. W V Med J 1997; 93: 264-266.
10. Fisher ER, Costantino JP, Leon ME et al.. Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21. Cancer 2007; 110: 1929-1936.
11. Gonzalez-Angulo AM, Litton JK, Broglio KR et al.. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27: 5700-5706.
12. Hanrahan EO, Valero V, Gonzalez-Angulo AM et al. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. J Clin Oncol 2006; 24: 2113-2122.
13. Colleoni M, Rotmensz N, Peruzzotti G et al.. Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. Ann Oncol 2004; 15: 1633-1639.
14. Curigliano G, Viale G, Bagnardi V et al.. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009; 27: 5693-5699.
15. Joensuu H, Pylkkanen L, Toikkanen S. Late mortality from pT1N0M0 breast carcinoma. Cancer 1999; 85: 2183-2189.
16. Park YH, Kim ST, Cho EY et al.. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Breast Cancer Res Treat 2010; 119: 653-661.
17. Rodrigues MJ, Wassermann J, Albiges L et al.. Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas. J Clin Oncol 2010; 28: e541-e542.
18. Vincent-Salomon A, MacGrogan G, Couturier J et al.. Re: HER2 testing in the real world. J Natl Cancer Inst 2003; 95: 628; author reply 628-629.
19. Penault-Llorca F, Balaton A, Sabourin JC et al. Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines. Ann Pathol 2002; 22: 150-157.
20. Wolff AC, Hammond ME, Schwartz JN et al.. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
21. Gligorov J, Namer M. Recommandations pour la pratique clinique, Nice, Saint-Paul-de-Vence: et de trois! Oncologie 2009; 11: 495-496.
22. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with longterm follow-up. Histopathology 1991; 19: 403-410.
23. Groenwold RH, Hak E, Hoes AW. Quantitative assessment of unobserved confounding is mandatory in nonrandomized intervention studies. J Clin Epidemiol 2009; 62: 22-28.
24. Perry N, Broeders M, de Wolf C et al.. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis, 4th edition. Luxembourg: Office for Official Publications of the European Communities 2006.
25. Burstein HJ, Winer EP. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 2009; 27: 5671-5673.
26. Rakha EA, Martin S, Lee AH et al.. The prognostic significance of lymphovascular invasion in invasive breast carcinoma. Cancer 2012; 118: 3670-3680.
27. Joensuu H, Isola J, Lundin M et al.. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003; 9: 923-930.
28. McArthur HL, Mahoney KM, Morris PG et al.. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 2011; 117: 5461-5468.
29. Kiess AP, McArthur HL, Mahoney K et al.. Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer 2011; 118: 1982-1988.
30. Petrelli F, Barni S. Role of HER2-neu as a prognostic factor for survival and relapse in pT1a-bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis. Med Oncol 2012. March 14 [Epub ahead of print], doi: 10.1007/s12032-012-0201-4.
31. Seradour B, Allemand H, Weill A et al. Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006. Bull Cancer 2009; 96: E1-E6.
32. Kricker A, Farac K, Smith D et al.. Breast cancer in New South Wales in 1972-1995: tumor size and the impact of mammographic screening. Int J Cancer 1999; 81: 877-880.
33. Schootman M, Jeffe D, Reschke A et al. The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States. Breast Cancer Res Treat 2004; 85: 219-222.
34. Musolino A, Michiara M, Conti GM et al.. Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study. J Clin Oncol 2012; 30: 2362-2368.
35. Kelly CM, Pritchard KI, Trudeau M et al.. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol 2011; 22: 2387-2393.
36. Rodrigues MJ, Albiges-Sauvin L, Wassermann J et al. Evaluating the risk-benefit ratio of adjuvant trastuzumab-based therapy for T1a,bN0M0 HER2-positive breast carcinomas. Ann Oncol 2011; 22: 2530.